In the News – From NIH

Scientists identify gene variant that may protect against APOE e4-related Alzheimer’s risk.

Certain versions of the fibronectin 1 gene may protect people with the APOE ε4 gene from increased Alzheimer’s disease risk, according to an NIA-funded study. The findings, published in Acta Neuropathologica, could help scientists better understand how Alzheimer’s develops, and help them determine potential new research strategies.

Medicare data analysis shows radical and ethnic disparities in dementia care costs.

An analysis of Medicare claims data found that dementia care expenditures were higher for Black and Hispanic people than White beneficiaries. These NIA-funded study results were published in the Journal of the American Geriatrics Society.

TDP-43 function is lost a decade before LATE disease onset.

Molecular and cellular changes associated with LATE, a form of dementia, begin a decade before the formation of abnormal clusters of TDP-43 that contribute to neurodegeneration and cognitive decline. According to an NIA study published in Acta Neuropathologica, the brain changes associated with LATE have specific effects on memory decline and visual-spatial abilities in older adults.

---

Funding Opportunity

Imaging Research in Alzheimer’s and Other Neurodegenerative Diseases Program

The Association and ASNR are partnering to offer this unique funding program to leverage their respective expertise and their communities. The goal of The Alzheimer’s Association & The Foundation of the American Society of Neuroradiology Funding Opportunity, Imaging Research in Alzheimer’s and Other Neurodegenerative Diseases is to support the development of new novel imaging tools, to advance imaging-based research and to provide funding for novel and innovative imaging data analysis as relates to Alzheimer’s and related dementia

Program Key Dates

• Letter of Intent Launch: September 25, 2024 – Must be submitted online here.
• Letter of Intent Deadline: October 23, 2024, 5:00PM ET
• Letter of Intent Notification: Week of December 2, 2024
• Application Deadline (if invited to submit a full application): January 29, 2025, 5:00PM ET
• Application Review: January – May 2025
• Award Notification: by May 15, 2025

For more information and eligibility requirements visit: alz.org/grants

To inquire about eligibility, you can contact a member of the Alzheimer’s Association Grants staff at grantsapp@alz.org

---

Administrative Supplement Program to Add Fluid-based Biomarkers and APOE Genotyping to NINDS ADRD Human Subjects Research Grants

The purpose of this one-year administrative supplement is to provide support for currently active NINDS Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) awards to add/include APOE genotype and fluid-based AD/ADRD biomarkers to ongoing AD/ADRD human subjects research studies and generate new data that should enhance the clinical and scientific content of the study, now and in the future via data sharing

Application Due Date: November 11, 2024, by 5:00 PM

---

Workshops & Learning Opportunities

2024 Science of Alzheimer’s and Infections Disease Symposium

October 15, 2024 | 8AM – 5PM | Los Angeles, CA

Hear presentations from leading researchers in the field of pathogenic Alzheimer’s disease research. Networking/poster reception to follow.

Join the free event in-person or online. Register for this event by October 1, 2024.

---

Duke Dementia Family Caregiver Connections

Dementia 101

October 16, 2024 | 2PM – 3PM | Virtual

Join speaker Dr. Liza Genao with Duke Geriatrics Evaluation and Treatment Clinic discussing many topics on Dementia, including:

• What is Dementia?
• What are common symptoms?
• How is a diagnosis made?
• What treatments are available?

---